Gstalder, Cécile <br/><br/>
FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.  [electronic resource] 

 -  Molecular cancer therapeutics  10 2016 
 - 2465-2474 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-16-0167  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Basic Helix-Loop-Helix Transcription Factors--genetics<br/>Carcinoma, Renal Cell--drug therapy<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Disease Models, Animal<br/>Drug Resistance, Neoplasm<br/>Female<br/>Fingolimod Hydrochloride--pharmacology<br/>Gene Expression<br/>Humans<br/>Hypoxia--genetics<br/>Hypoxia-Inducible Factor 1, alpha Subunit--genetics<br/>Lysophospholipids<br/>Mice<br/>Neovascularization, Pathologic--drug therapy<br/>Oxygen Consumption<br/>Phosphotransferases (Alcohol Group Acceptor)--metabolism<br/>Receptors, Lysosphingolipid--metabolism<br/>Signal Transduction--drug effects<br/>Sphingosine--analogs & derivatives<br/>Vascular Endothelial Growth Factor A--biosynthesis<br/>Vascular Remodeling--drug effects<br/>Xenograft Model Antitumor Assays